Polyrizon shares surge 12.63% premarket after partnering with Clearmind to develop intranasal MEAI formulation.

Polyrizon Ltd. (PLRZ) surged 12.63% in premarket trading following the announcement of a strategic collaboration with Clearmind Medicine Inc. (CMND) to develop an intranasal formulation of MEAI, a non-hallucinogenic neuroplastogen targeting addiction and central nervous system (CNS) disorders. The partnership leverages Polyrizon’s proprietary intranasal delivery technology, which aims to enhance drug bioavailability, patient usability, and targeted CNS delivery. The agreement, described as both scientifically and strategically significant, aligns with Polyrizon’s focus on advancing its hydrogel-based delivery platforms for pharmaceutical applications. CEO Tomer Izraeli emphasized the potential for the collaboration to strengthen Polyrizon’s position as a key player in intranasal drug delivery. The news directly addresses market interest in innovative therapeutic solutions and validates the company’s technology, driving immediate investor optimism.